Get the Stockscreener App
52.71
5.61%
-3.13
After Hours:
52.71
Soleno Therapeutics Inc stock is traded at $52.71, with a volume of 1.23M.
It is down -5.61% in the last 24 hours and down -6.36% over the past month.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
See More
Previous Close:
$55.84
Open:
$55.02
24h Volume:
1.23M
Relative Volume:
1.94
Market Cap:
$2.27B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-17.40
EPS:
-3.03
Net Cash Flow:
$-24.94M
1W Performance:
-8.77%
1M Performance:
-6.36%
6M Performance:
+22.90%
1Y Performance:
+85.40%
1-Day Range:
$51.39
$55.27
1-Week Range:
$51.39
$60.92
52-Week Range:
$27.27
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.71 | 2.27B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Short Interest in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Drops By 23.2% - MarketBeat
Baird maintains Outperform on Soleno, keeps $72 target - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Vestal Point Capital LP - MarketBeat
Victory Capital Management Inc. Buys 2,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Receives FDA Extension for DCCR Review - Defense World
PDUFA target action date for Soleno’s DCCR extended by three months - The Pharma Letter
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire Inc.
FDA delays decision of Soleno’s Prader-Willi syndrome drug - Pharmaceutical Technology
What the Options Market Tells Us About Soleno Therapeutics - Benzinga
FDA extends review of Soleno's Prader-Willi syndrome drug - Investing.com India
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment - Yahoo Finance
FDA extends review of Soleno's Prader-Willi syndrome drug By Investing.com - Investing.com Canada
Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment - Seeking Alpha
Soleno Therapeutics Announces FDA Extension of Review - GlobeNewswire
Capnia stock soars to 52-week high, hits $60 milestone By Investing.com - Investing.com South Africa
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Capnia stock soars to 52-week high, hits $60 milestone - Investing.com
495,708 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Westfield Capital Management Co. LP - MarketBeat
Soleno Therapeutics Reports Q3 Progress and Financials - TipRanks
PERCEPTIVE ADVISORS LLC Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Perceptive Advisors LLC Increases Stake in Soleno Therapeutics I - GuruFocus.com
Objective long/short (SLNO) Report - Stock Traders Daily
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - The Manila Times
Soleno Therapeutics Announces Oral Presentations featuring - GlobeNewswire
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc - GuruFocus.com
Soleno Therapeutics' SWOT analysis: rare disease stock poised for FDA decision - Investing.com Australia
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation - Yahoo Finance
HC Wainwright Reiterates Buy Rating for Soleno Therapeutics (NASDAQ:SLNO) - MarketBeat
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth - Simply Wall St
Harbor Capital Advisors Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Soleno Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Capnia Inc stock soars to 52-week high, hits $58 mark - Investing.com
(SLNO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Target Price at $69.86 - Defense World
Emerald Advisers LLC Grows Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $73.00 at Oppenheimer - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week High Following Analyst Upgrade - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stake Boosted by Allspring Global Investments Holdings LLC - Defense World
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth By Investing.com - Investing.com South Africa
Soleno Therapeutics shares remain Outperform as analyst lifts price target on updated sales projections - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth - Investing.com India
Oppenheimer Boosts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $73.00 - MarketBeat
Soleno Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
(SLNO) Technical Data - Stock Traders Daily
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. - GlobeNewswire
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):